Bioequivalence studies are a mandatory step in the registration of most generic medicinal products. These studies demonstrate that a generic drug is as effective and safe as the reference (originator) product.

In 2026, the bioequivalence research market in Russia continues to grow rapidly. Pharmaceutical companies are seeking to accelerate market access for their products, while regulatory authorities are imposing increasingly stringent requirements on data quality, study conduct, and statistical analysis.

What Is a Bioequivalence Study?
A bioequivalence study is a clinical trial that compares:

• the rate of drug absorption;
• the extent of active substance absorption;
• the concentration of the drug in the bloodstream.

The primary objective is to demonstrate that the generic product is equivalent to the reference product in terms of its key pharmacokinetic parameters.
In simple terms, the regulatory authority must be satisfied that the generic product:

• has a pharmacological profile comparable to that of the originator product;
• provides an equivalent therapeutic effect;
• has a comparable safety profile.

When Is a Bioequivalence Study Required?
Bioequivalence studies are typically required:

• for the registration of generic medicinal products;
• when changes are made to the product formulation;
• when the manufacturing process is modified;
• when the dosage form is changed;
• for certain combination medicinal products.

How Is a Bioequivalence Study Conducted?
Study Design
The most common study design is:

• randomized;
• crossover;
• comparative.

Participants receive:

• the investigational (test) product;
• the reference (originator) product.

The following pharmacokinetic parameters are then compared:

• Cmax — maximum plasma concentration;
• AUC — area under the concentration-time curve;
• Tmax — time to reach maximum concentration.

Who Participates in the Study?
Bioequivalence studies are generally conducted in:

• healthy volunteers;
• men and women aged 18–45 years.

The number of participants depends on:

• the variability of the drug;
• the study design;
• the required statistical power.

Typically, studies include:

• 24 to 72 volunteers.

For highly variable drugs, substantially larger sample sizes may be required.
Key Requirements for Bioequivalence Studies
In 2026, bioequivalence studies must comply with:

• Good Clinical Practice (GCP);
• Eurasian Economic Union (EAEU) requirements;
• Russian regulatory legislation;
• applicable international guidelines.

What Do Regulatory Authorities Evaluate?
Regulators pay particular attention to:

• protocol quality;
• compliance with randomization procedures;
• investigational product storage conditions;
• laboratory methodologies;
• statistical analysis;
• completeness of study documentation.

Even minor deficiencies may result in:

• regulatory comments;
• the need to repeat the study;
• refusal of marketing authorization.

Stages of a Bioequivalence Study
1. Protocol Development
During the planning stage, the following are determined:

• study design;
• number of volunteers;
• dosing regimen;
• blood sampling schedule;
• statistical analysis methods.

Recommendation
A well-developed protocol significantly reduces the likelihood of regulatory queries and repeat studies.
2. Regulatory Approvals
Before the study begins, it is necessary to:

• obtain approval from the Ministry of Health of the Russian Federation;
• receive approval from an Ethics Committee;
• arrange insurance coverage for study volunteers.

Average approval timeline:

• 1–3 months.

3. Volunteer Recruitment
For bioequivalence studies, particular attention is paid to:

• compliance with inclusion criteria;
• absence of significant concomitant diseases;
• adherence to study requirements.

Important
Errors during volunteer selection may affect study outcomes and increase data variability.
4. Clinical Phase
The clinical phase includes:

• administration of study medications;
• collection of blood samples;
• continuous safety monitoring of volunteers;
• clinical laboratory assessments.

Most bioequivalence studies are conducted in an inpatient clinical research unit.
5. Laboratory Analysis
Following completion of the clinical phase, the following activities are performed:

• determination of drug concentrations;
• pharmacokinetic analysis;
• statistical evaluation of study data.

This stage is critical for obtaining reliable and scientifically valid results.
6. Final Study Report
The final documentation package includes:

• the Clinical Study Report (CSR);
• statistical safety analysis;
• analytical, validation, and statistical reports related to bioanalytical testing;
• documentation required for product registration.

How Much Does a Bioequivalence Study Cost in Russia in 2026?
The overall cost depends on:

• product complexity (e.g., combination products, highly variable drugs, etc.);
• number of volunteers;
• number of study periods;
• duration of hospitalization;
• scope of laboratory testing;
• extent of bioanalytical work.

Average Costs
What Is Included in the Budget?
A typical study budget covers:

• protocol development;
• regulatory support;
• clinical site activities;
• volunteer hospitalization;
• laboratory testing;
• bioanalytical services, including preparation of validation, analytical, and statistical reports;
• biostatistics;
• data management;
• preparation of the final study report.

Project Timeline
Typical project timelines in 2026 are as follows:
Overall Project Duration
On average, a complete bioequivalence study requires:

• 5–6 months.

How to Choose a Bioequivalence Research Center
When selecting a research site, consider:

• experience in conducting similar studies;
• availability of an in-house clinical research unit;
• capabilities of the bioanalytical laboratory;
• speed of volunteer recruitment;
• successful experience with regulatory inspections;
• quality of statistical analysis.

Conclusion
A bioequivalence study is a critical stage in the registration of a generic medicinal product and directly influences the speed of market entry.
The success of a project depends on:

• a well-designed study protocol;
• the experience of the clinical research center;
• the reliability of the laboratory;
• robust statistical analysis;
• full compliance with regulatory requirements.

Certa Clinic and its experienced research team provide comprehensive, turnkey bioequivalence study services—from protocol development and regulatory documentation to the preparation of the final Clinical Study Report.
We offer:

• rapid project initiation;
• professional regulatory and scientific support;
• a modern clinical research facility and analytical laboratory;
• full compliance with international quality standards;
• transparent, flexible, and cost-effective budgeting.

If you are planning a bioequivalence study, our team is ready to provide an efficient and reliable solution to help bring your medicinal product to market as quickly as possible.